BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28158230)

  • 1. The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays.
    Pieters M; Barnard SA; Loots DT; Rijken DC
    PLoS One; 2017; 12(2):e0171271. PubMed ID: 28158230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
    Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
    Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia.
    Gilabert J; Estellés A; Aznar J; España F; Andrés C; Santos T; Vallés J
    Thromb Haemost; 1990 Jun; 63(3):361-6. PubMed ID: 2144918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
    Torr-Brown SR; Sobel BE
    Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
    Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
    J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic activity and platelet release reaction in essential hypertension.
    Keskin A; Tombuloglu M; Büyükkeçeci F
    Jpn Heart J; 1994 Nov; 35(6):757-63. PubMed ID: 7897822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the release of a plasminogen activator inhibitor by human platelets.
    Kruithof EK; Tran-Thang C; Bachmann F
    Thromb Haemost; 1986 Apr; 55(2):201-5. PubMed ID: 2940723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
    Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
    Thromb Res; 1998 Apr; 90(2):51-6. PubMed ID: 9684757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing effect of platelets on staphylokinase-mediated clot lysis and plasminogen activation.
    Suehiro A; Tsujioka H; Yoshimoto H; Ueda M; Higasa S; Kakishita E
    Thromb Res; 1995 Oct; 80(2):135-42. PubMed ID: 8588190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A history of early stent thrombosis is associated with prolonged clot lysis time.
    Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
    Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic imbalance in essential thrombocythemia: role of platelets.
    Bazzan M; Tamponi G; Gallo E; Stella S; Schinco PC; Pannocchia A; Pileri A
    Haemostasis; 1993; 23(1):38-44. PubMed ID: 8477907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
    Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
    J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen levels of plasminogen activator inhibitor type 1 in citrated plasma: determination of the contribution of platelets.
    Grimaudo V; Bachmann F; Kruithof EK
    Haemostasis; 1990; 20(6):329-33. PubMed ID: 2151572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-induced release of plasminogen activator from human blood platelets.
    Kahn NN; Bauman WA; Sinha AK
    Am J Physiol; 1995 Jan; 268(1 Pt 2):H117-24. PubMed ID: 7530914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.
    Loza JP; Gurewich V; Johnstone M; Pannell R
    Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.